ישראל - עברית - Ministry of Health

אפריל רשת חנויות בעמ - שיפור מראה העור

ישראל - עברית - Ministry of Health

manon pharm ltd. - ascorbic acid; betacarotene; biotin; calcium carbonate; calcium pantothenate; chromium as chloride; colecalciferol; copper; cyanocobalamin; ferrous fumarate; folic acid; magnesium oxide; manganese as sulfate; nicotinamide; potassium iodide; pyridoxine (vit b6) hydrochloride; riboflavine; sodium molybdate; sodium selenate; thiamine (vit b1) mononitrate; tocopherol (vit e) (as tocopheryl acetate); vitamin a; zinc as oxide - טבליה - betacarotene 1500 iu; vitamin a 1500 iu; ascorbic acid 100 mg; folic acid 1 mg; riboflavine 3.4 mg; nicotinamide 20 mg; cyanocobalamin 12 mcg; colecalciferol 250 iu; biotin 30 mcg; copper 2 mg; sodium molybdate 25 mcg; manganese as sulfate 5 mg; zinc as oxide 25 mg; ferrous fumarate 60 mg; potassium iodide 0.15 mg; magnesium oxide 50 mg; chromium as chloride 25 mcg; calcium pantothenate 10 mg; pyridoxine (vit b6) hydrochloride 10 mg; thiamine (vit b1) mononitrate 3 mg; tocopherol (vit e) (as tocopheryl acetate) 30 iu; calcium carbonate 250 mg; sodium selenate 25 mcg - vitamin and mineral supplement for use during pregnancy and lactation.

ישראל - עברית - Ministry of Health

meditrend marketing (2004) ltd, israel - benzoxonium chloride; chlorhexidine as gluconate; vitamin a palmitate - משחה - vitamin a palmitate 0.2 %w/w; benzoxonium chloride 0.1 %w/w; chlorhexidine as gluconate 0.5 %w/w - chlorhexidine, combinations - chlorhexidine, combinations - disinfection of minor superficial wounds, minor burns (first degree).

ישראל - עברית - Ministry of Health

sam-on ltd - vitamin d3 - טבליה - vitamin d3 1000 iu - colecalciferol

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - ascorbic acid; biotin; colecalciferol; cyanocobalamin; dexpanthenol; folic acid; nicotinamide; phytomenadione; pyridoxine (vit b6) hydrochloride; riboflavine; thiamine (vit b1) hydrochloride; tocopherol (vit e) (as tocopheryl acetate); vitamin a palmitate - תוסף לתמיסה לאינפוזיה - ascorbic acid 80 mg / 4 ml; vitamin a palmitate 2300 iu / 4 ml; colecalciferol 400 iu / 4 ml; thiamine (vit b1) hydrochloride 1.2 mg / 4 ml; riboflavine 1.4 mg / 4 ml; nicotinamide 17 mg / 4 ml; pyridoxine (vit b6) hydrochloride 1 mg / 4 ml; dexpanthenol 5 mg / 4 ml; tocopherol (vit e) (as tocopheryl acetate) 7 iu / 4 ml; phytomenadione 0.2 mg / 4 ml; folic acid 140 mcg/ml; biotin 20 mcg/ml; cyanocobalamin 1 mcg/ml - multivitamins and other minerals, incl. combinations - multivitamins and other minerals, incl. combinations - for use as a multiple vitamin supplement for infants and children up to 11 years of age. it is also indicated in other situations where there are increased requirements for vitamins due to stress situations such as surgery, extensive burns, fractures and other trauma, severe infectious diseases, and comatose states. the physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. the use of a multivitamin product obviates the need to speculate on the status of individual vitamin nutriture.

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 30000 iu / 0.75 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 4000 iu / 0.4 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 5000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob